Yukun Tan

Yukun Tan

Auto-generated profile, based on publicly available information

Yukun Tan

Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2025 in Nature
Verified
Journal Article
Open access
HRHind Rafei
Hind Rafei
RBRafet Basar
Rafet Basar
SASunil Acharya
Sunil Acharya
YHYu-Sung Hsu
Yu-Sung Hsu
PLPinghua Liu
Pinghua Liu
KRKatayoun Rezvani
Katayoun Rezvani
Chimeric antigen receptor (CAR) natural killer (NK) cell immunotherapy offers a promising approach against cancer1-3. However, the molecular mechanisms that regulate CAR-NK cell activity remain unclear. Here we identify the transcription factor cyclic AMP response element modulator (CREM) as a crucial regulator of NK cell function. Transcriptomic analysis revealed a significant induction of CREM in CAR-NK cells during the peak of effector function after adoptive transfer in a tumour mouse model, and this peak coincided with signatures of both activation and dysfunction. We demonstrate that both CAR activation and interleukin-15 signalling rapidly induce CREM upregulation in NK cells. Functionally, CREM deletion enhances CAR-NK cell effector function both in vitro and in vivo and increases resistance to tumour-induced immunosuppression after rechallenge. Mechanistically, we establish that induction of CREM is mediated by the PKA-CREB signalling pathway, which can be activated by immunoreceptor tyrosine-based activation motif signalling downstream of CAR activation or by interleukin-15. Finally, our findings reveal that CREM exerts its regulatory functions through epigenetic reprogramming of CAR-NK cells. Our results provide support for CREM as a therapeutic target to enhance the antitumour efficacy of CAR-NK cells.

17 August 2023 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
JDJinzhuang Dou
Jinzhuang Dou
YTYukun Tan
Yukun Tan
KKKian Hong Kock
Kian Hong Kock
JWJun Wang
Jun Wang
XCXuesen Cheng
Xuesen Cheng
Ken ChenKen Chen
Ken Chen
Single-cell omics technologies enable molecular characterization of diverse cell types and states, but how the resulting transcriptional and epigenetic profiles depend on the cell’s genetic background remains understudied. We describe Monopogen, a computational tool to detect single-nucleotide variants (SNVs) from single-cell sequencing data. Monopogen leverages linkage disequilibrium from external reference panels to identify germline SNVs and detects putative somatic SNVs using allele cosegregating patterns at the cell population level. It can identify 100 K to 3 M germline SNVs achieving a genotyping accuracy of 95%, together with hundreds of putative somatic SNVs. Monopogen-derived genotypes enable global and local ancestry inference and identification of admixed samples. It identifies variants associated with cardiomyocyte metabolic levels and epigenomic programs. It also improves putative somatic SNV detection that enables clonal lineage tracing in primary human clonal hematopoiesis. Monopogen brings together population genetics, cell lineage tracing and single-cell omics to uncover genetic determinants of cellular processes.

30 April 2024 in Journal of Biomedical Informatics
Verified
Journal Article
Closed access
YTYukun Tan
Yukun Tan
MDMerve Dede
Merve Dede
VMVakul Mohanty
Vakul Mohanty
JDJinzhuang Dou
Jinzhuang Dou
HHHolly Hill
Holly Hill
Ken ChenKen Chen
Ken Chen

10 November 2020 in IEEE/ACM Transactions on Computational Biology and Bioinformatics
Verified
Journal Article
Closed access
YTYukun Tan
Yukun Tan
Fernando BuarqueFernando Buarque
Fernando Buarque
UBUlisses M. Braga-Neto
Ulisses M. Braga-Neto
We present PALLAS, a practical method for gene regulatory network (GRN) inference from time series data, which employs penalized maximum likelihood and particle swarms for optimization. PALLAS is based on the Partially-Observable Boolean Dynamical System (POBDS) model and thus does not require ad-hoc binarization of the data. The penalty in the likelihood is a LASSO regularization term, which encourages the resulting network to be sparse. PALLAS is able to scale to networks of realistic size under no prior knowledge, by virtue of a novel continuous-discrete Fish School Search particle swarm algorithm for efficient simultaneous maximization of the penalized likelihood over the discrete space of networks and the continuous space of observational parameters. The performance of PALLAS is demonstrated by a comprehensive set of experiments using synthetic data generated from real and artificial networks, as well as real time series microarray and RNA-seq data, where it is compared to several other well-known methods for gene regulatory network inference. The results show that PALLAS can infer GRNs more accurately than other methods, while being capable of working directly on gene expression data, without need of ad-hoc binarization. PALLAS is a fully-fledged program, written in python, and available on GitHub ( https://github.com/yukuntan92/PALLAS ).

27 November 2025 in npj Parkinson's Disease
Verified
Journal Article
Open access
PDF file
RJRoshni Jaffery
Roshni Jaffery
YZYuhang Zhao
Yuhang Zhao
SASarfraz Ahmed
Sarfraz Ahmed
JSJackson G. Schumacher
Jackson G. Schumacher
JAJae Ahn
Jae Ahn
XCXiqun Chen
Xiqun Chen
Mutations in LRRK2 , a leading genetic cause of Parkinson’s disease (PD), are linked to immune dysregulation, but the immune profiles in the periphery and central nervous system (CNS) remain incompletely defined. This study utilized a large cohort of serum samples ( n = 651) and matched CSF samples ( n = 129) from LRRK2 mutation carriers and non-carriers, with and without PD, to assess immune regulators using Luminex immunoassay. After correction for multiple comparisons, LRRK2 mutations were associated with significantly elevated serum levels of SDF-1 alpha and TNF-RII, while CSF markers such as BAFF, CD40L, and IL-27 were nominally reduced. Regardless of LRRK2 status, PD was associated with nominally lower levels of inflammatory analytes in CSF, with minimal changes observed in serum. Correlation analyses revealed distinct immune profiles between serum and CSF, suggesting compartmentalized immune responses. These findings highlight immune alterations in LRRK2 mutation carriers and PD, providing potential serum markers for monitoring immune responses and avenues for mechanistic studies.

24 March 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
RJRoshni Jaffery
Roshni Jaffery
YZYuhang Zhao
Yuhang Zhao
SASarfraz Ahmed
Sarfraz Ahmed
JSJackson G. Schumacher
Jackson G. Schumacher
JAJae Ahn
Jae Ahn
XCXiqun Chen
Xiqun Chen
Background and Objectives: Mutations in the Leucine-rich repeat kinase 2 ( LRRK2 ) gene are one of the most common genetic causes of Parkinson’s disease (PD) and are linked to immune dysregulation in both the central nervous system and periphery. However, peripheral and central profiles of soluble immune factors associated with LRRK2 mutations and PD have not been comprehensively characterized. Using serum and CSF samples from the LRRK2 Cohort Consortium (LCC), this study aimed to probe a broad range of soluble immune biomarkers associated with LRRK2 mutations and PD. Methods: We investigated the levels of soluble immune regulators in the serum (n=651) and cerebrospinal fluid (CSF, n=129) of LRRK2 mutation carriers and non-carriers, both with and without PD. A total of 65 cytokines, chemokines, growth factors, and soluble receptors were assessed by Luminex immunoassay. A multivariable robust linear model was used to determine levels associated with LRRK2 mutations and PD status, adjusting for age, sex, and sample cohort. Correlations were assessed using the Spearman correlation coefficient. LRRK2 G2019S knock-in mice were used to validate the associations identified in the LCC. Results: In this extensive discovery cohort, we identified several elevated serum immune regulatory factors associated with LRRK2 mutations. In particular, serum stromal cell-derived factor-1 alpha (SDF-1 alpha) levels, as supported by findings in LRRK2 G2019S knock-in mice, and tumor necrosis factor receptor II (TNF-RII) were significantly increased after multiple comparison adjustment. In contrast, LRRK2 mutations were associated with reduced soluble immune markers, including BAFF, CD40-Ligand, I-TAC, MIP-3 alpha, NGF beta, and IL-27 in CSF. Those with clinically diagnosed PD, with or without LRRK2 mutations, did not show strong signals in serum but reduced inflammatory analytes in CSF, including MIF, MMP-1, CD30, Tweak, and SDF-1 alpha. In addition, we found that the serum levels of these soluble immune factors display varied correlations with their corresponding CSF levels. Discussion: This study highlights distinct immune profiles associated with LRRK2 mutations and PD in the periphery and CNS. Serum levels of SDF-1alpha and TNF-RII were elevated in LRRK2 mutation carriers, while CSF immune markers were reduced. In PD, irrespective of LRRK2 status, reduced CSF inflammatory analytes and weak serum signals were observed. These results provide insight into immune dysregulation linked to LRRK2 mutations. If replicable in independent datasets, they offer potential avenues for biomarker and therapeutic exploration.